Haemonetics (HAE) Earnings: Q2 Fiscal 2027 Results and Next Report Date

The quarter ended September 26, 2026 and Haemonetics published the results on November 5, 2026. Revenue and diluted EPS are shown against Q2 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. Haemonetics reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Haemonetics' fiscal year ends on the Saturday closest to the last day of March. Q2 fiscal 2027 ended September 26, 2026, and fiscal 2027 includes a 53rd week, which the company estimates adds about 2% to reported revenue growth.
• Organic revenue growth excludes currency and the exit of certain liquid solution products, and includes nominal pre-acquisition revenue of Vivasure, acquired in January 2026.

Source: Haemonetics Q2 fiscal 2027 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 26, 2026. Figures as reported; checked against the release on November 10, 2026.

How Haemonetics splits revenue in its own release, under its own labels, for Q2 fiscal 2027 against Q2 fiscal 2026. Indented lines are parts of the line above them.

• Haemonetics's Apheresis revenue was $205 million in Q2 fiscal 2027, up 13% from $182 million in Q2 fiscal 2026, 57% of total revenue.
• Haemonetics's MedSurg revenue was $153 million in Q2 fiscal 2027, up 5% from $145 million in Q2 fiscal 2026, 43% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Haemonetics gives its fiscal 2027 outlook as a table in the release. Current guidance: reported revenue growth of 8% to 11% (previously 5% to 8%), including about 2% from the 53rd week, organic revenue growth of 6% to 9% (previously 4% to 7%), adjusted operating margin expansion of 0 to 50 basis points (previously 50 to 100), adjusted EPS growth comparable to reported revenue growth, and free cash flow conversion above 80% (previously about 80%).

In its Q2 fiscal 2027 release, Haemonetics said:

“Current guidance includes high-single-digit growth in Apheresis and mid-single digit growth in MedSurg.”

“Free cash flow conversion is calculated as free cash flow divided by adjusted net income.”

Source: Haemonetics Q2 fiscal 2027 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the HAE forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenues and diluted EPS, each as first reported in that quarter's release. The Q4 fiscal 2026 loss followed an impairment of intangible assets related to Attune Medical.

Haemonetics's next report is expected around February 4, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q2 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q2 fiscal 2027 (this page), reported Nov 5, 2026

Haemonetics had net revenues of $357.8 million in Q2 fiscal 2027, up 9.3% from $327.3 million, and organic revenue growth of 10.0%. It reports two business units: Apheresis, $204.8 million, up 12.6%, and MedSurg, $153.0 million, up 5.1%. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026)

Plasma, the devices and disposables Haemonetics sells to plasma collectors, is the largest product line at $162.6 million, up 16.5% reported and 17.7% organically. Haemonetics said the Apheresis increase was primarily volume growth and share gains within the Plasma franchise. The rest of Apheresis, blood collection and processing devices and disposables, was flat at $42.2 million. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026; Haemonetics Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Plasma revenue depends on a few customers. In fiscal 2026 one Plasma customer accounted for about 13% of total net revenues and the ten largest customers for about 44%. On August 14, 2026, Haemonetics signed a non-exclusive supply agreement under which CSL Plasma may use its NexSys PCS devices with Persona PLUS technology in the United States, and CSL has said it anticipates moving all its current US plasma collection centers to Haemonetics devices and disposables. (Haemonetics Form 10-K, fiscal 2026, May 20, 2026; Haemonetics Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Within MedSurg, Blood Management Technologies (hemostasis management, cell salvage and transfusion management) grew 7.0% to $92.4 million on volume and share gains, and Interventional Technologies (vascular closure, sensor-guided technologies and esophageal protection) grew 2.4% to $60.5 million. By region, the United States contributed $267.8 million of the $357.8 million, Europe $46.6 million and Japan $16.1 million. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026; Haemonetics Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Haemonetics earned $1.00 per diluted share under GAAP in Q2 fiscal 2027, up 23.5% from $0.81, on net income of $46.3 million. Adjusted EPS was $1.35, up 6.3% from $1.27. The largest adjustments were amortization of acquired intangible assets ($0.18 a share), digital transformation costs ($0.09) and integration and transaction costs ($0.05). (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026)

GAAP gross margin rose to 61.7% from 59.5%, which Haemonetics attributed to tariff refunds, a shift toward higher-margin products and the absence of inventory step-up amortization. The year-ago GAAP quarter also carried an $8.6 million impairment of intangible assets. The effective tax rate rose to 26.3% from 24.6% because of valuation allowances in jurisdictions with losses from recent acquisitions. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026)

Diluted weighted average shares fell to 46.5 million from 47.7 million. Haemonetics made no share repurchases in the first half of fiscal 2027, against $75.0 million a year earlier, and used cash to pay down the revolving credit facility it drew to settle its 2026 convertible notes; $200.0 million remained outstanding on September 26, 2026. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026; Haemonetics Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Haemonetics publishes a fiscal-year outlook in its release and raised its revenue range with Q2 fiscal 2027 results: reported revenue growth of 8% to 11%, up from 5% to 8%, and organic growth of 6% to 9%, up from 4% to 7%. The organic range now includes high-single-digit growth in Apheresis and mid-single digit growth in MedSurg. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026)

Haemonetics lowered its adjusted operating margin outlook to 0 to 50 basis points of expansion, from 50 to 100 basis points, and expects adjusted EPS growth comparable to reported revenue growth and free cash flow conversion above 80%. It does not reconcile these forward non-GAAP figures to GAAP. (Haemonetics Q2 fiscal 2027 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Haemonetics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Haemonetics's own release and filings put weight on for Q2 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning HAE is on is HAE a buy or a sell?, what analysts expect next is on the HAE forecast, and what the company does is on the Haemonetics (HAE) stock page.

Every number on this page can be traced to a document Haemonetics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.